Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease

Autor: Shuchita Kaila, Mary DuCharme, Swetha R Palli, Ami R Buikema, Monica Frazer, Timothy Juday
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
medicine.drug_class
Pulmonary disease
Muscarinic Antagonists
Medicare
Inverse probability of treatment weighting
Insurance Claim Review
Pulmonary Disease
Chronic Obstructive
03 medical and health sciences
0302 clinical medicine
Adrenal Cortex Hormones
Internal medicine
medicine
Humans
030212 general & internal medicine
Tiotropium Bromide
Adrenergic beta-2 Receptor Agonists
Aged
Aged
80 and over
COPD
business.industry
β2 agonists
Health Policy
Tiotropium-olodaterol
Muscarinic antagonist
Pneumonia
Middle Aged
medicine.disease
United States
Benzoxazines
Bronchodilator Agents
Drug Combinations
Models
Economic
Treatment Outcome
030228 respiratory system
Disease Progression
Corticosteroid
Drug Therapy
Combination
Female
Health Expenditures
business
medicine.drug
Zdroj: Journal of Comparative Effectiveness Research. 8:1299-1316
ISSN: 2042-6313
2042-6305
DOI: 10.2217/cer-2019-0101
Popis: Aim: To compare health plan-paid costs, exacerbations and pneumonia outcomes for patients with chronic obstructive pulmonary disease (COPD) initiating combination tiotropium olodaterol (TIO + OLO) versus triple therapy (TT: long-acting muscarinic antagonist + long-acting β 2 agonists + inhaled corticosteroid). Patients & methods: COPD patients initiating TIO + OLO or TT between 1 January 2014 and 30 June 2016 were identified from a managed care Medicare database and balanced for baseline characteristics using inverse probability of treatment weighting before assessment of outcomes. Results: Annual COPD-related and all-cause costs were US$4118 (35%) and US$5384 (23%) lower for TIO + OLO versus TT (both p ≤ 0.001). TIO + OLO patients had nearly half the severe exacerbations (8.3 vs 15.5%; p = 0.014) and pneumonia was also less common (18.9 vs 30.9%; p Conclusion: TIO + OLO was associated with improved economic and COPD health outcomes versus TT.
Databáze: OpenAIRE
Externí odkaz: